Skip to main content
. 2013 Jan 8;18(1):27–36. doi: 10.1634/theoncologist.2011-0380

Table 1.

Response rates and outcomes in phase III trials of VMP, MPT, and MPR-R versus MP

graphic file with name onc00113-1138-t01.jpg

aComplete plus partial response, assessed by European Group for Blood and Marrow Transplantation criteria.

bPooled odds ratio in favor of MPT.

Abbreviations: CR, complete response; IFM, Intergroupe Francophone du Myelome; MM, multiple myeloma; MP, melphalan and prednisone; MPR-R, MP plus lenalidomide with lenalidomide maintenance; MPT, MP plus thalidomide; NR, not reported; ORR, overall response rate; OS, overall survival; TTP, time to progression; VISTA, Velcade as Initial Standard Therapy in Multiple Myeloma; VMP, bortezomib plus MP.